Group 1 - The core point of the news is that Jinbo Bio plans to raise up to 2 billion yuan through a strategic investment from Yangshengtang, marking the largest cash private placement in the history of the Beijing Stock Exchange [1] - Jinbo Bio's controlling shareholder, Yang Xia, will transfer 5% of the company's shares to Hangzhou Jiushi at a price of 243.84 yuan per share, totaling 1.403 billion yuan [1] - After the transaction, Zhong Shanshan will hold a total of 10.58% of Jinbo Bio's shares through Yangshengtang and Hangzhou Jiushi [1] Group 2 - The raised funds will be used for the development of a humanized collagen protein FAST database and product development platform, as well as to supplement working capital [2] - The collaboration is expected to accelerate the implementation of Jinbo Bio's strategy of "technological products becoming everyday products and medical products becoming consumables" [2] - Jinbo Bio specializes in the research, production, and sales of medical devices and functional skincare products, focusing on recombinant collagen products and anti-HPV biological protein products [2] Group 3 - Jinbo Bio's revenue is projected to grow from 233 million yuan in 2021 to 1.443 billion yuan in 2024, with net profit increasing from 57.39 million yuan to 732 million yuan during the same period [3] - The company's gross margin is expected to rise from 82.29% in 2021 to 92.02% in 2024, indicating improving profitability [3]

Trading Volume and Market Activity - On June 27, the total trading volume of stocks on the Beijing Stock Exchange reached 1.438 billion shares, with a total transaction value of 34.758 billion yuan, a decrease of 5.541 billion yuan compared to the previous trading day [1] - Among the tradable stocks, 152 stocks closed higher, accounting for 56.93% of the total, with notable gainers including Guangxin Technology, Guoyuan Technology, and Tianma New Materials, which rose by 17.78%, 16.50%, and 11.84% respectively [1] - Conversely, 109 stocks closed lower, with the largest declines seen in Youji Co., *ST Yunchuang, and Tonghui Information, which fell by 14.81%, 8.68%, and 8.27% respectively [1] Stock Performance and Turnover Rates - A total of 106 stocks had transaction values exceeding 10 million yuan, with the highest transaction values recorded for Jinbo Biological, Guangxin Technology, and Tonghui Information at 1.250 billion yuan, 931 million yuan, and 901 million yuan respectively [1] - The trading activity indicated that 70 stocks had a turnover rate exceeding 10%, with 20 stocks exceeding 20%. Additionally, 67 stocks had turnover rates between 5% and 10%, while 128 stocks had rates between 1% and 5% [1] - The stocks with the highest turnover rates included Tonghui Information, Guangxin Technology, and Youji Co., with rates of 53.91%, 47.42%, and 37.19% respectively [1] Notable Stocks and Their Metrics - The closing prices and performance metrics of notable stocks included: - Jinbo Biological: Closing price of 348.80 yuan, up 8.67%, turnover rate of 5.87%, transaction value of 1.250 billion yuan [1] - Guangxin Technology: Closing price of 70.67 yuan, up 17.78%, turnover rate of 47.42%, transaction value of 931 million yuan [1] - Tonghui Information: Closing price of 11.20 yuan, down 8.27%, turnover rate of 53.91%, transaction value of 901 million yuan [1] - Guoyuan Technology: Closing price of 19.70 yuan, up 16.50%, turnover rate of 34.76%, transaction value of 612 million yuan [1] - Tianma New Materials: Closing price of 40.82 yuan, up 11.84%, turnover rate of 18.40%, transaction value of 592 million yuan [1]

Core Viewpoint - The recent stock issuance by Jinbo Biological, controlled by Zhong Shanshan, aims to raise up to 2 billion RMB to support its growth and development in the collagen market, while also indicating a strategic partnership with Yangshengtang [1][2][7]. Group 1: Company Actions and Financials - Jinbo Biological plans to issue no more than 717,566 shares, representing 6.24% of its total shares before the issuance, to raise funds for a humanized collagen protein database and working capital [1][2]. - The total investment for the projects is 200 million RMB, with 57.5% allocated to the collagen protein project and 42.5% for working capital [2]. - Jinbo Biological's stock price has surged since its listing, with a maximum increase of over 800% from its issue price, reaching a peak of 452.29 RMB [3][9]. Group 2: Market Performance and Growth - Jinbo Biological has shown impressive financial growth, with revenue increasing from 233 million RMB in 2021 to 1.443 billion RMB in 2024, and net profit rising from 57.39 million RMB to 732 million RMB in the same period [9]. - The gross margin improved from 82.29% to 92.02%, and net margin increased from 24.38% to 50.68% [9]. - The Chinese collagen market reached 28.7 billion RMB in 2021, growing at 40.7%, with a significant increase in the penetration of recombinant collagen [9]. Group 3: Strategic Partnerships and Future Outlook - Yangshengtang, controlled by Zhong Shanshan, is entering into a strategic partnership with Jinbo Biological, which is expected to enhance business synergies and accelerate the implementation of their strategic goals [7][8]. - The collaboration aims to leverage technological integration and market channel empowerment, potentially leading to significant advancements in product development [7][8]. - Jinbo Biological's need for strategic investors is highlighted by its relatively small size and the increasing competition in the medical aesthetics industry [10][13].

Core Viewpoint - Jinbo Biological has signed a share subscription agreement with Yangshengtang to issue shares aimed at integrating resources and advancing the industrialization of recombinant human collagen technology, marking a deep strategic partnership between the two companies [1][3] Group 1: Financial Details - Jinbo Biological plans to issue up to 7.18 million shares at a price of 278.72 RMB per share, raising a total of up to 2 billion RMB, with a lock-up period of 36 months [1] - If the 2 billion RMB private placement is successfully implemented, it will be the largest cash private placement in the history of the Beijing Stock Exchange [2] - The actual controller of Jinbo Biological, Yang Xia, has signed a transfer agreement with a subsidiary of Yangshengtang to transfer 5% of shares at a price of 243.84 RMB per share, totaling 1.4 billion RMB, which is also the largest transfer amount on the Beijing Stock Exchange [2] Group 2: Strategic Cooperation Benefits - The partnership will leverage Yangshengtang's extensive retail network, facilitating Jinbo Biological's product penetration into consumer markets, transitioning from professional medical applications to everyday health consumption [3] - Yangshengtang's large-scale industrial production system and supply chain management will enhance the efficiency of Jinbo Biological's technology transfer and shorten product launch cycles [3] - The collaboration will promote research applications of recombinant human collagen in serious medical fields, benefiting from Yangshengtang's strong R&D capabilities in vaccines and biomedicine [3] Group 3: Future Development Plans - The funds raised will primarily be used for the development of a FAST database and product development platform for human collagen, as well as to supplement working capital [4] - The strategic cooperation is expected to solidify Jinbo Biological's leadership in the recombinant human collagen sector and contribute to the high-quality development of China's biotechnology industry [4] - The partnership aims to provide competitive Chinese innovations to the global market and offer consumers better health solutions [4]

Market Overview - As of 13:59 today, the Shanghai Composite Index is at 3424.00 points, below the five-day moving average, with a decline of 0.71% [1] - The total trading volume of A-shares today is 12836.21 billion [1] Stocks Breaking the Five-Day Moving Average - A total of 319 A-shares have broken above the five-day moving average today [1] - The stocks with the largest deviation rates include: - Maiwei Biological with a deviation rate of 12.67%, closing at 28.62 yuan, up 20.00% [2] - Zhuyou Group with a deviation rate of 7.86%, closing at 11.28 yuan, up 10.05% [2] - Zhongfu Industrial with a deviation rate of 7.33%, closing at 4.48 yuan, up 9.80% [2] - Other notable stocks with smaller deviation rates include: - Dongxing Medical, Haipu Rui, and Laobaixing, which have just crossed the five-day moving average [1] Detailed Stock Performance - The following stocks have notable performance metrics: - Jiayou International: 9.97% increase, 10.81 yuan latest price, 7.22% deviation [2] - Jinjing Pharmaceutical: 10.39% increase, 17.00 yuan latest price, 6.70% deviation [2] - Xin Henghui: 12.94% increase, 53.07 yuan latest price, 6.17% deviation [2] - Additional stocks with significant trading activity include: - Hasa Lian: 9.97% increase, 14.45 yuan latest price, 5.89% deviation [2] - Huayang New Materials: 9.97% increase, 6.84 yuan latest price, 5.85% deviation [2]

证券代码：832982 证券简称：锦波生物 公告编号：2025-085 山西锦波生物医药股份有限公司 关于召开 2025 年第二次临时股东会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 公司同一股东只能选择现场投票、网络投票中的一种方式，如果同一表 决票出现重复投票表决的，以第一次投票表决结果为准。 一、会议召开基本情况 （一）股东会届次 本次会议为 2025 年第二次临时股东会。 （二）召集人 本次股东会的召集人为董事会。 2025 年 6 月 26 日，公司第四届董事会第十二次会议审议通过了《关于提 请召开公司 2025 年第二次临时股东会的议案》。 （三）会议召开的合法合规性 本次股东会的召集、召开所履行的程序符合《公司法》和《公司章程》的 有关规定。会议召开无需相关部门批准或履行必要程序。 （五）会议召开日期和时间 1、现场会议召开时间：2025 年 7 月 14 日 14：30。 2、网络投票起止时 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-080 山西锦波生物医药股份有限公司 监事会关于公司向特定对象发行股票相关事项的 书面审核意见 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律 责任。 根据《中华人民共和国公司法》《中华人民共和国证券法》和《北京证券交 易所上市公司证券发行注册管理办法》等相关法律、法规和规范性文件的规定， 结合公司实际情况并经认真核查，我们作为公司的监事，在认真审阅了公司董事 会编制的《山西锦波生物医药股份有限公司2025年度向特定对象发行股票募集说 明书（草案）》及提供的相关资料后，经审慎思考，依据公平、公正、客观的原 则，现就公司2025年度向特定对象发行股票（以下简称"本次发行"）相关事项 发表如下意见： 一、关于《关于公司符合2025年度向特定对象发行股票条件的议案》的审 查意见 根据《中华人民共和国公司法》《中华人民共和国证券法》和《北京证券交 易所上市公司证券发行注册管理办法》等相关法律、法规和规范性文件的规定， 经过对公司实际情况及相关事项进行逐项认 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-072 山西锦波生物医药股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 6 月 26 日 2.会议召开地点：公司四楼会议室 3.会议召开方式：现场加通讯 4.发出监事会会议通知的时间和方式：2025 年 6 月 26 日以电话方式发出（按照监 事会议事规则采用即时通讯方式发出会议通知 ） 5.会议主持人：监事会主席汤莉女士 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关法 律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于公司符合 2025 年度向特定对象发行股票条件的议案》 1.议案内容： 根据《中华人民共和国公司法》《中华人民共和国证券法》和 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-071 山西锦波生物医药股份有限公司 第四届董事会第十二次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 6 月 26 日 2.会议召开地点：公司四楼会议室 3.会议召开方式：现场加通讯 4.发出董事会会议通知的时间和方式：2025 年 6 月 26 日以电话方式发出（按 照董事会议事规则采用即时通讯方式发出会议通知 ） 5.会议主持人：董事长杨霞女士 6.会议列席人员：汤莉、于玉凤、何振瑞、薛芳琴、兰小宾 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关法 律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事金雪坤、王玲玲、张金鑫、阎丽明、梁桐栋因出差或外地办公以通讯方 式参与表决。 二、议案审议情况 （一）审议 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-083 山西锦波生物医药股份有限公司 简式权益变动报告书 信息披露义务人及其主要负责人保证公告内容的真实、准确和完整，不存 在虚假记载、误导性陈述或者重大遗漏。 信息披露义务人保证除本报告书披露的信息外，没有通过任何其他方式增 加或减少其在上市公司中拥有权益的股份。 上市公司名称：山西锦波生物医药股份有限公司 注册地址：山西综改示范区太原唐槐园区锦波街 18 号 股票简称：锦波生物 股票代码：832982.BJ 信息披露义务人 1：久视管理咨询（杭州）合伙企业（有限合伙） 执行事务合伙人：新泉咨询管理（丽水）合伙企业（有限合伙） 注册地址：浙江省杭州市西湖区转塘街道葛衙庄 181 号 2 号楼 C205 权益变动性质：股份增加（股份协议转让） 信息披露义务人 2：养生堂有限公司 法定代表人：钟睒睒 注册地址：浙江省杭州市西湖区双浦镇夏铜街 1 号 3 幢 3 层 1 权益变动性质：股份增加（特定对象发行），本次取得上市公司发行的新股尚 需 2025 年第二次临时股东会审议通过，尚需经北京证券交易所审核通过并经中 国证监会作出同意注册的决定后方可实 ...